Commercialization

The Center for Stem Cell and Regenerative Medicine has had five new business formations since its inception in 2003. Four are continuing operations.

  • Arteriocyte, Inc. (Jan. 2004) use of stem cell technology to increase blood flow with initial focus on cardiovascular applications.
  • Juventas Therapeutics (Sept. 2004) use of molecular cues and stem cells to increase myocardial repair after myocardial infarction.
  • Cell Targeting, Inc. (Nov. 2004) use of transient molecular markers to direct cell homing.
  • Invenio Therapeutics, Inc. (June 2007) drug that terminally differentiates leukemia cells.

For more information on these companies, please click on the company names above or email Michael Gilkey, Marketing and Operations Manager, at stemcellcenter@case.edu.


For commercialization, licensing and/or partnership opportunities, please call Michael Gilkey at 216.368.2079 or send an email to stemcellcenter@case.edu.